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Abstract 
 
Fsp27 (CIDEC the human homologue) is a lipid droplet protein that when overexpressed down 
regulates fatty acid oxidation (FAO). Previous results of this group showed that Fsp27/CIDEC 
expression is regulated by fasting in liver in a time-dependent manner. The present study aimed 
to elucidate the mechanism by which Fsp27/CIDEC is mediating fasting adaptation and 
regulated by FAO rate in liver. We showed that induction of Fsp27/CIDEC expression during 
fasting is not regulated by PPARα. Pharmacological inhibition of FAO by etomoxir induces 
Fsp27/CIDEC in fasting conditions and this regulation is not mediated by PPAR – a master 
regulator in triglyceride accumulation. The early response to fasting can be explained by a 
canonical PKA-CREB-CRTC2 signaling pathway, since CIDEC expression was increased by 
forskolin which effect was lost when a vector containing a dominant negative of CREB construct 
(KCREB) was co-transfected in HepG2 cells, and, consistently, Fsp27 promoter activity was 
increased by CREB. Also, CIDEC expression was up-regulated by specific Sirt1 depletion by 
siRNA in HepG2 cells. Our data demonstrate that Fsp27/CIDEC is a CREB target gene that 
could be up-regulated when FAO is reduced and that fluctuations in SIRT1 activity, in response 
to nutrient availability, mediate this mechanism.  
The peroxissome proliferator-activated receptor gamma coactivator-1α (PGC-1α) induces and 
coordinates gene expression that stimulates metabolic pathways linked to the fasted response 
in liver including gluconeogenesis. We observed that Pgc-1α expression was increased in late 
fasting in the liver of mice previously subjected to a leucin deprived diet. These conditions also 
enhanced transcription from Foxa2 gene. This study showed that the mechanism regulating the 
induction of Pgc-1α expression under these conditions is not mediated by the recruitment of 
CREB by Foxa2 to the Pgc-1α or the Pepck promoters, since both promoters activities were not 
enhanced by the co-transfection of FOXA2 with CREB in HepG2 cells. 
 
Keywords: CIDEC/Fsp27; Fasting; FAO; CREB; SIRT1; Amino-acid deprivation; PGC-1α; 
FOXA2. 
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Resumo 
 
Fsp27 (CIDEC, o homologo humano) é uma proteina associada às gotas lipídicas que quando 
sobre-expressada inibe a oxidação dos ácidos gordos (FAO). Recentemente, resultados deste 
grupo demonstraram que a sua expressão é regulada durante o estado de jejum no fígado no 
decurso do tempo. Neste estudo pretende-se elucidar o mecanismo pelo qual Fsp27/CIDEC 
medeia a adaptação ao jejum e a sua regulação pela taxa de FAO no fígado.  Demonstrou-se 
que a sua indução durante o jejum não é regulada por PPARα e a indução registada pela 
inibição farmacológica da FAO por etomoxir não é mediada por PPAR – regulador crucial na 
acumulação de triglicéridos. A resposta à fase inicial do jejum explica-se pela via de sinalização 
PKA-CREB-CRTC2 uma vez que a expressão de CIDEC aumentou com forskolina  e este 
efeito foi atenuado com a transfecção de um dominante negativo de CREB em células HepG2. 
Consistentemente, a actividade do promotor Fsp27 aumentou com CREB. A indução da 
expressão de CIDEC observou-se com a supressão específica de Sirt1 por siRNA em células 
HepG2. Estes resultados demonstram que Fsp27/CIDEC é um gene alvo de CREB cuja 
expressão aumenta com redução da FAO e este processo é mediado pela actividade de 
SIRT1. 
PGC-1α  induz e coordena a expressão genética que estimula processos metabólicos 
relacionados com a resposta ao jejum no fígado incluindo a gluconeogenese. Observou-se que 
a  sua expressão aumenta na fase tardia do jejum no fígado de ratos previamente sujeitos a 
uma dieta sem leucina, condições que induziram a transcrição do gene Foxa2. Este estudo 
demonstrou que o mecanismo que regula a indução da expressão de Pgc-1α  nestas condições 
não é mediada pelo recrutamento de CREB por Foxa2 para os promotores Pgc-1α e Pepck, 
uma vez que ambas as actividades promotoras não foram induzidas pela transfecção 
simultânea de FOXA2 com CREB em células HepG2. 
  
Palavras Chave:  CIDEC/Fsp27; Jejum; FAO; CREB; SIRT1; Deprivação de aminoácidos; 
PGC-1α; FOXA2. 
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1. INTRODUCTION 
 
1.1. Fasting 
 
Mammals have evolved a metabolic response system that allows them to survive during long 
periods of energy deprivation. The overall metabolic response to fasting operates at numerous 
levels. One prominent feature is the gradual shift in whole-body fuel utilization from 
carbohydrates and fat in the fed state to almost exclusively fat after a day of fasting [1]. This 
adaptation is particularly striking in the brain, an obligate glucose utilizer in the fed state, which 
is able to acquire energy predominantly from ketone bodies after prolonged fasting [2,3]. The 
main metabolic fuels of the human body are glucose, fatty acids and ketone bodies. Its principal 
energy stores are liver glycogen, adipose tissue triglyceride and muscle protein. Most of the 
actual inter-conversions in energy substrates occur in liver, which plays a central role in the 
adaptive response to fasting [4].  
Prolonged fasting is characterized by low insulin concentrations, high glucagon, glucocorticoids 
and epinephrine concentrations in plasma (Figure 1.1). In feeding/fasting conditions, these 
counter regulatory hormones will maintain blood glucose levels [5]. 
In this state liver degrades glycogen into glucose. In addition, it receives glucogenic amino acids 
such as alanine and lactate (from muscle) and glycerol (from adipose tissue) which are 
precursors for gluconeogenesis or de novo synthesis of glucose [4]. Gluconeogenesis it is a 
highly polarized metabolic pathway involving biochemical reactions in different compartments 
such as the cytoplasm, mitochondria, endoplasmic reticulum and plasma membrane. The rate 
of gluconeogenesis is controlled by three key enzymes: phosphoenol-pyruvate carboxykinase 
(PEPCK), fructose 1,6-bisphosphatase and glucose-6-phosphatase (G6P). Hormonal control of 
these enzymes is achieved at the transcriptional level. The main positive signals to turn on 
gluconeogenesis are activated during fasting, stress and diabetes. As already referred, among 
these signals is glucagon that produces an increase in intracellular cAMP and glucocorticoids, 
endogenous ligands for the glucocorticoid receptor [5].  
The fasting liver also receives non-esterified fatty acids (mainly long chain fatty acids), released 
from adipose tissue triglycerides [5]. The hormonal profile of the fasted state promotes the 
hydrolysis of triacylglycerol in adipose tissue, thereby increasing the concentration of free fatty 
acids (FFA) in plasma. The fatty acids are taken up by the liver, where they are either re-
esterified to triacylglycerol and secreted as very-light-density lipoproteins (VLDL) or oxidized in 
the mitochondria via β-oxidation. The majority of fatty acids are only partially oxidized to acetyl-
coenzyme A (acetyl-CoA), which then condenses with itself to form ketone bodies, an important 
fuel to the brain [6].  
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Figure 1.1. The fasting state: The gluconeogenic liver. 
 In fasting conditions, the liver becomes the principle source of glucose for the brain. Liver glycogen is 
brake down, and the glucose 1-phosphate produced is converted to glucose 6-phophate, then to free 
glucose, which is released into the blood stream. Amino acids from the degradation of proteins and 
glycerol from the breakdown of triglycerides in adipose tissue are used for gluconeogenesis. The liver 
uses fatty acids as its principal fuel, and excess acetyl-CoA is converted to ketone bodies for export to 
other tissues for fuel; the brain is especially dependent on this fuel when glucose is in short supply. 
Adapted from Lehninger, Principles of Biochemistry 2005 [5]. 
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1.2. Molecular mechanisms regulating adaptation to fasting 
 
1.2.1. CREB/CRTC2 Signaling Pathway 
 
Circulating glucose levels reflect a balance between glucose production by the liver and glucose 
utilization by skeletal muscle. The liver, a key target of both insulin and glucagon signaling, 
contributes to the control of glucose metabolism by facilitating glucose uptake and output 
depending on the physiological condition [7]. Under fasting conditions, mammals initiate a whole 
body metabolic response that limits glucose and favors fatty acid oxidation. In these conditions 
the liver is central in the metabolic response to glucagon, epinephrine and glucocorticoids, 
which act to stimulate hepatic glucose via glycolysis and gluconeogenesis in order to prevent 
extend periods of hypoglycemia [8].  
The gluconeogenic program is largely regulated at the transcriptional level, by the cyclic AMP 
(cAMP) responsive element binding protein (CREB) and its ability to activate PGC-1α (PPAR 
gamma coactivator- 1α) [9].  This response is dependent on the phosphorylation of CREB at 
Ser133 mediated by protein kinase A (PKA) and the subsequent recruitment of the coactivators 
CREB binding protein (CBP)/p300 to promoters of gluconeogenic genes (such as PEPCK and 
G6P) [9]. The simplicity of this model, has been challenged with the discovery of the CREB-
regulated transcription coactivator 2 (CRTC2) [10] which has been implicated as the foremost 
mediator driving CREB target expression [11]. 
In fact, CRTC2 was described as a critical component of the early transcriptional fasting 
response in the liver by acting up-stream of PGC-1α in the gluconeogenic pathway [12, 13].  
In the early state of fasting, circulating glucose and insulin levels are low, glucagon and/or 
epinephrine signaling results in the dephosphorylation of CRTC2 and its translocation to the 
nucleus where it drives the transcription of several genes implicated in gluconeogenesis by 
specifically interacting with CREB and facilitating recruitment of the coactivators CBP and p300 
to CREB target sequences. Following long-term stimulation, it has been proposed that CRTC2 
is deacetylated by SIRT1 and targeted for degradation in proteasome (Figure 1.2) [13]. Sirtuin 1 
(SIRT1) is a type III NAD
+ 
dependent deacetylase (its role will be further explored in the next 
section). 
CRTC2 activity is also controlled by insulin signaling which results in CRTC2 phosphorylation 
and exclusion from the nucleus where it can no longer impact gene expression [14]. 
Interestingly, whereas the increase in SIRT1 activity that accompanies prolonged fasting 
attenuates CRTC2 signal, it actually improves PGC-1α’s ability to increase hepatic 
gluconeogenesis [15]. In fact, maintenance of the gluconeogenic response through prolonged 
fasting will be mediated by PGC-1α and Forkhead box O1 (FOXO1) (Figure 1.2) [13].  
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Figure 1.2. Schematic diagram of the inducible switch that modulates gluconeogenesis through the 
CREB/CRTC2 signaling pathway. 
 Fasting corresponds to a metabolic state where insulin levels are low and glucagon levels are high and it 
can be dissected in two distinct phases, the early phase (<12-18h) and late phase (>12-18h). CRTC2 – 
CREB regulated transcription coactivator  2; CREB - cAMP responsive element binding protein, FOXO1 - 
Forkhead box protein O1 , PGC-1α - Peroxissome proliferator-activated receptor gamma coactivator- 1α, 
SIRT1 – Sirtuin 1. 
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1.2.2. SIRT1 
 
Caloric restriction causes many changes in glucose metabolism [16]. Recently, it was 
suggested a model in which protein acetylation regulates metabolic strategy and also helps 
store energy in cells [17]. In the cell, acetylation is carried out by histones acetyl transferases 
(HATs) and deacetylation by class I, II and III deacetylases. The type III, NAD
+ 
dependent 
deacetylase is termed sirtuins [17]. Among sirtuins, SIRT1 – which modulates ageing in several 
species [18, 19] – appears to be involved in a great number of physiological pathways, including 
gluconeogenic/glycolytic pathways in liver in response to fasting signals through the 
transcriptional coactivator PGC-1α [20]. Also, SIRT1 is known to target MyoD, p53 and forkhead 
transcription factors for deacetylation [21, 22]. 
SIRT1 seems to be involved in pathways affected directly by caloric restriction in mammals [23]. 
Several studies showed that SIRT1 activity is low in growth conditions of glucose excess and 
high during energy limitation [15, 16]. This behavior is due to SIRT1 being a NAD-dependent 
deacetylase. In energy abundance conditions, there is ATP generation trough glycolysis and 
conversion of NAD to NADH in mitochondria and therefore SIRT1 activity is expected to 
decrease.  This behavior suggests a feed forward mechanism, in which diet drives glycolysis, 
convert NAD to NADH, inactivate sirtuins, and increase acetylation and activity of glycolytic 
enzymes [17]. Conversely, under fasting or low nutrient conditions, limit glycolysis, activate 
SIRT1 triggering protein deacetylation in mitochondria. These conditions, fit with one of the 
main outputs of SIRT1 activity, the deacetylation of PGC-1α to promote mitochondrial 
biogenesis and oxidative metabolism [15] (Figure 1.2). 
This evidence, suggest protein acetylation as a regulatory mechanism, as well as energy-
storage mechanism when energy is in excess. The regulatory aspects include histone 
acetylation to regulate gene transcription, acetylation of metabolic enzymes to favor glycolysis 
for ATP production, and acetylation of several transcription factors such as p53, FOXO1, PGC-
1α, nuclear receptors to adjust expression levels of pathways for oxidative versus glycolytic 
metabolism [24]. Regarding the transcription factors, SIRT1 has mainly been linked to negative 
regulation of gene expression through protein deacetylation (e.g. p53) [25, 26]; however it can 
act both positively and negatively to control gene expression as PGC-1α [15] in response to 
NAD
+
 fluctuations in accordance to nutrient availability [13, 15, 16, 23].  
The storage aspect of acetylation may be important in transitioning from energy access to 
energy limitation. Under these conditions, the acetate generated by SIRT1 deacetylation of 
many proteins would be a substract for acetyl-CoA synthethase. Along with the oxidation of fatty 
acids, would drive the citric acid cycle and oxidative phosphorylation to yield ATP and CO2 [17]. 
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1.2.3. PGC-1α  
 
One of the components of the signal transduction pathway involved in metabolic reprogramming 
is the peroxissome proliferator-activated receptor gamma coactivator-1α – PGC-1α. This 
transcriptional co-activator is able to coordinate the expression of a wide array of genes 
involved in glucose and fatty acid metabolism [3].  
 
Molecular mechanisms of PGC-1α function 
 
PGC-1α was first identified as a binding partner and co-activator of the transcriptional activity of 
PPAR [27]. It is known to bind and consequently modulate the activity of a wide range of 
transcription factors such as PPARα, glucocorticoid receptor, hepatic nuclear factor-4α 
(HNF4α), members of the estrogen related receptor (ERR) family, Foxo1, among others [28, 
29]. 
Once it is activated, PGC-1α is recruited to the chromatin through interaction with transcription 
factors [30]. After docking to a transcription factor, PGC-1α undergoes a conformational change 
that allows interaction with histone acetyl transferases (HAT) such as CBP/p300 and steroid 
receptor coactivator (SRC-1). This set of proteins interacts at the PGC-1α N-terminal region that 
contains a potent transcriptional activation domain. Although they enhance the activity of PGC-
1α, SRC-1 and CBP/300 do not acetylate PGC-1α. In fact, acetylation of PGC-1α, is correlated 
to a decrease in its activity [15].  
This data reveal that the regulation of gene expression by PGC-1α is achieved by a sequential 
and dynamic recruitment of different set of proteins making a functional multiprotein complex 
that transcribes specific genes. 
 
From a physiological standpoint, the co-activation of these transcription factors by PGC-1α has 
important metabolic repercussions. Specifically, this set of transcription factors to which PGC-1α 
binds, controls the expression of genes involved in adaptive thermogenesis, gluconeogenesis, 
glycolysis, lipogenesis,  mitochondrial fatty acid oxidation, and mitochondrial respiration 
efficiency [3]. Thus, PGC-1α can single coordinate gene expression of multiple energy 
pathways. This point is based in studies where PGC-1α knockout mouse, shows a reduced 
respiratory capacity, reduces rates of hepatic gluconeogenesis and β-oxidation, hepatic 
steatosis under fasting conditions and hypoglycemia [31, 32].  
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PGC-1α in the adaptation to food deprivation 
 
In terms of its contribution to the diet-dependent maintenance of energy homeostasis in 
mammals, there is a body of evidence to suggest that the co-transcriptional activity of PGC-1α 
is important to the compensatory metabolic responses that occur during food deprivation [3, 33].  
During fasting, gluconeogenesis is profoundly up regulated primarily at the level of transcription. 
As already described (in CREB/CRTC2 signaling pathway section) a compelling argument can 
be made for dissecting the up regulation of gluconeogenesis into two temporally distinct phases 
[13].  Regarding the adaptation to the maintenance of the gluconeogenic response through 
prolonged fasting is thought to be mediated by PGC-1α and its transcription factors [3]. Indeed, 
in the late state of fasting, the elevated levels of PGC-1α facilitate increased hepatic glucose 
output by promoting the expression of gluconeogenic genes [29]. This regulation is mediated by 
the hormones that signal fasting such as glucagon and insulin [34] but also by SIRT1 mediated 
deacetylation [15]. 
As discussed above, during fasting glucagon activate via cAMP, the CREB transcription factor, 
an important regulator of PGC-1α gene expression [9]. In addition, glucocorticoids strongly 
synergize with cAMP to induce PGC-1α levels. Under this state, of lower nutrient availability, 
intracellular NAD
+
 levels increase which leads to the deacetylation of PGC-1α by SIRT1 [35]. 
The change in PGC-1α  acetylation coincides with an increased activation of PGC-1α  which 
binds and co-activates different transcription factors such as HNF4α and FOXO1 and 
glucocorticoid receptors (GR) to coordinate expression of gluconeogenic genes [33, 36]. Insulin, 
a dominant-negative signal suppresses PGC-1α expression in liver (Figure 1.3) [34].  
 
FOXO1 acts as a cellular sensor of insulin signaling via Akt. Akt phosphorylates FOXO1 and 
induces cytoplasmic localization and degradation. PGC-1α requires FOXO1 to bind and localize 
to the promoter chromatin region of gluconeogenic genes [33]. This mechanism, corresponds 
with the re-feeding state were PGC-1α activity decreases. 
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Figure 1.3. Transcriptional regulation of hepatic gluconeogenesis by PGC-1 alpha.  
Hepatic glucose production in the liver is tightly controlled by hormones. Glucagon and catecholamines 
stimulate the cAMP pathway and CREB, which activates PGC-1α gene expression. PGC-1α is then 
recruited to different transcription factors that bind to the promoter of gluconeogenic genes such as 
PEPCK. Glucocorticoids induce a specific interaction between PGC-1α and GR-activating PEPCK. Insulin 
represses cAMP activation on gluconeogenic genes, but how it blocks PGC-1α gene expression is 
unknown. Adapted from Puigserver et al., 2003 [34]. 
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1.2.4. FOXA2 
 
A complex network functions to maintain whole body homeostasis of metabolites such as 
glucose and amino acids. One group of such genes is FOXA (forkhead box A) family, also 
known as hepatic nuclear factor 3 (HNF3) [32]. The mammalian FOXA family consists of three 
members, FOXA 1, FOXA2 and FOXA3, which contribute to embryonic development [37] and to 
hormonal control of gene expression [38]. FOXA proteins bind to similar recognition sequences 
and the proteins are proposed to have redundant function in regulating some of their target 
genes [39]. The Foxa genes appear to be involved in the protection of the organism from 
hypoglycemia [40, 41].  However, each FOXA protein has distinct functions.  
 
Foxa2 is involved in the mechanisms regulating fasting and amino acid deprivation. 
 
In the liver, some Foxa target genes identified are involved in glucose homeostasis, particularly 
in the response to fasting [42]. Examples include the gluconeogenic enzymes 
phosphoenolpyruvate carboxykinase (Pepck), glucose-6-phosphatase (G6p) and tyrosine 
aminotransferase (Tat) [39].  
The role of Foxa2 in hepatic glucose homeostasis was evaluated by Zhang et al [42], by genetic 
approach using a mouse model in which Foxa2 was deleted specifically from hepatocytes. 
Although these mice were normoglycemic, they fail to fully activate Pepck and Tat in response 
to fasting. Furthermore, this group suggested that Foxa2 mediates activation of guconeogenic 
genes by enabling recruitment of CREB and glucocorticoid receptors to their target sites in 
chromatin [42]. The results of this study suggest that Foxa2 is required for execution of hepatic 
gluconeogenic program, by integrating the transcriptional response of the hepatocyte to 
hormonal regulation during fasting. 
Recent work from Wolfrum and colleagues [43, 44] has introduced a new concept regarding 
Foxa2 in nutrient metabolism. They have shown that in cultured cells the transcriptional activity 
of Foxa2 is blocked by treatment with insulin, and that this regulation requires an intact 
phosphorylation site for the insulin-activated kinase of mouse Foxa2. This phosphorylation is 
reported to result in nuclear exclusion of Foxa2, thereby providing an appealing molecular 
model in which Foxa2’s gluconeogenic activity is blocked via feeding-induced insulin secretion 
[43, 44]. 
The authors proposed a model in which Foxa2 is nuclear only in the starved state, during which 
it activates multiple genes driving increased hepatic glucose utilization, fatty acid oxidation, and 
ketogenesis. 
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Further, it was observed that under amino acid deprivation of HepG2 hepatoma cells 
transcription of the Foxa2 gene was enhanced [45]. However, this activation did not required 
activation of the transcription factor 4 (ATF4), a critical component of the conventional amino 
acid response (AAR) pathway (this pathway will be discussed in ‘’Amino Acid deprivation” 
section), but Foxa2 induction was partially dependent on CCAAT/enhancer-binding protein β 
(which is induced upon amino acid deprivation) [45]. The results presented in this study 
suggested that Foxa family of genes is differentially regulated by amino-acid availability. 
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1.3. Fatty Acid Signal Transduction Pathway  
 
1.3.1. Fatty Acid Oxidation 
 
In the transition from the fed to the fasted state the liver switches from an organ of carbohydrate 
utilization and fatty acid synthesis to one of fatty acid oxidation and ketone body production. The 
fasted state is associated with mobilization of stored lipid in white adipose tissue and increase in 
fatty acid flux through the mitochondrial β-oxidation [46].   
 
β-oxidation is the major process by which fatty acids are oxidized, thus providing a major source 
of energy for the heart and skeletal muscle [47, 48]. β-oxidation is stimulated during starvation 
or endurance exercise [6] . 
 
Fatty Acids are Activated and Transported into Mitochondria 
 
The β-oxidation of activated fatty acids occurs within the mitochondrial matrix and is catalyzed 
by the sequential action of four enzyme families (acyl CoA dehydrogenase, enoyl-CoA 
hydratase, 3-hydroxyacyl-CoA dehydrogenase and 3-ketoacyl- CoA thiolase) each with different 
substrate specificity for short-, medium, and long-chain acyl-CoAs. Long-chain fatty acids are 
activated on the mitochondrial outer membrane by the long-chain acyl-CoA synthetase (LCAS) 
but the mitochondrial inner membrane is not permeable to these acyl-CoAs. The carnitine 
dependent transport of these activated fatty acids precedes their β-oxidative chain shortening 
[49]. 
 
This transport system consists of three proteins: carnitine palmitoytranferase I (CPT-I), carnitine 
acylcarnitine translocase (CACT) and carnitine palmitoyltransferase II (CPT-II), each with a 
different submitochondrial localization. As a first step, acyl CoAs formed by the catalytic action 
of LCAS in the mitochondrial outer membrane are converted to acylcarnitines. This 
transterification is catalyzed by CPT-I also localized in the mitochondrial outer membrane. The 
reaction products, long-chain acylcarnitines, are then translocated into the mitochondrial matrix 
in an exchange reaction catalyzed by CACT, an integral inner membrane protein. Within the 
matrix the acylcarnitines are then reconverted to the respective acyl-CoAs by CPT-II, an 
enzyme associated with the mitochondrial inner membrane (Figure 1.4) [50]. 
The carnitine-mediated entry process is the rate limiting step for oxidation of fatty acids in 
mitochondria and it is an important point of regulation [5]. 
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Oxidation of Fatty Acids  
 
Mitochondial β-oxidation of fatty acids takes place in three stages. In the first stage (β-oxidation) 
the fatty acids undergo oxidative removal of successive two carbon units in the form of acetyl-
CoA [50].   
In the second stage of fatty acid oxidation, the acetyl groups of acetyl CoA are oxidized to CO2 
in the citric cycle, which take place in the mitochondrial matrix. The first two stages of fatty acid 
oxidation produce the reduced electron carriers NADH and FADH2, which in the third stage 
donate electrons to the mitochondrial respiratory chain, through which the electrons pass to 
oxygen with the concomitant phosphorylation of ADP to ATP. The energy released by fatty acid 
oxidation is conserved as ATP [6]. 
 
 
 
 
 
 
 
 
 
Figure 1.4. Fatty acid entry into mitochondria via acyl carnitine/carnitine transporter.  
After fatty acyl-carnitine is formed at the outer membrane in the intermembrane space, it moves into the 
matrix by facilitated diffusion through the transporter in the inner membrane. In the matrix, the acyl group 
is transferred to mitochondrial coenzyme A, freeing carnitine to return to the inter-membrane space 
through the same transporter. Acyl transferase I is inhibited by malonyl CoA. This inhibition prevents the 
simultaneous synthesis and degradation of fatty acids. Adapted from Lehninger, Principles of 
Biochemistry 2005 [5]. 
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Hepatic regulation of mitochondrial β-oxidation 
 
Much of the control and regulation of the rate of hepatic mitochondrial β-oxidation appears to 
reside at the level of the entry of acyl groups into mitochondria. 
Malonyl-CoA is the first intermediate in the cytosolic biosynthesis of long-chain fatty acids from 
acetyl-CoA, increases in concentration whenever the body is well supplied with carbohydrate; 
excess glucose that cannot be oxidized or stored as glycogen is converted in the cytosol into 
fatty acids for storage as triacylglycerol. The inhibition of CPT-I by malonyl CoA ensures that the 
oxidation of fatty acids is inhibited in the fed state [6, 50]. 
 
 
 
 
1.3.2. Ketogenesis 
 
Ketogenesis becomes significant under conditions of food (carbohydrate) deprivation. Provision 
of peripheral tissues, such as skeletal muscle and heart, with ketone bodies as an alternative 
fuel for energy production, results in glucose sparing for organs depending on glucose as an 
energy source [51, 52]. The ketone bodies play an important role in this adaptation: starvation 
induces an increase in plasma ketone bodies concentration and turnover serving as an 
important fuel for the central nervous system [53]. 
In fasting conditions the liver needs to maintain the Krebs cycle for ATP production and 
gluconeogenesis for supplying glucose for extrahepatic tissues. Since these two processes 
require the same intermediates, having oxaloacetate as rate-limiting enzyme, both begin to slow 
down. As a result acetyl CoA accumulates in the mitochondria [54]. Through a serie of 
condensation reactions (Figure 1.5), ketone bodies (acetoacetate, β-hydroxybutyrate and 
acetone) are produced [53].  
The sum of these reactions is β-hydroxybutyrate, formed by the reduction of acetoacetate in the 
mitochondrial matrix with the generation of NAD
+
 (Figure 1.5) [55]. 
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Although fatty acids are by far the major carbon donors, for ketone body synthesis, the 
catabolism of some (ketogenic) amino acids also provides carbon atoms for ketogenesis, either 
via acetyl-CoA or directly by yielding acetoacetate [52]. 
Control of ketogenesis is exerted by transcriptional regulation of mitochondrial 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA) synthase 2 (HMGCS2) [51, 52, 56]. The transcriptional rate of 
this rate-limiting enzyme increases in response to cAMP, starvation, fat feeding and diabetes 
while insulin and refeeding repress it [57, 58]. Regarding to its transcriptional control, results of 
this group suggested that HMGCS2 expression is affected by the PPARα-mediated response 
and it is also involved in the induction of β-oxidation [59]. 
 
 
 
Figure 1.5. Formation of ketone bodies from acetyl-CoA. Adapted from Lehninger, Principles of 
Biochemistry 2005 [6]. 
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1.3.3. PPARs 
 
Nutrient availability impact gene expression mainly by activating or suppressing specific 
transcription factors [60]. The most important group of transcription factors involved in mediating 
the effect of nutrients and their metabolites one gene transcription is the superfamily of nuclear 
receptors [61]. Several studies have shown that a group of nuclear hormone receptors, the 
peroxisome proliferator-activated receptors (PPARs), have an important role in fatty acid 
metabolism [62]. 
 
Nuclear receptors govern gene expression via several distinct mechanisms that involve both 
activation and repression of DNA transcription. PPARs are members of the nuclear hormone 
superfamily. [63].   Transcriptional regulation by PPARs requires heterodimerization with the 
retinoid X receptor (RXR) which is also part of the nuclear receptor superfamily. When activated 
by a ligand, the PPAR/ RXR heterodimer stimulates transcription via binding to DNA response 
elements – PPAR response elements (PPRE) – present in the promoter of target genes [64]. 
The PPAR family consists in three isotypes: α, δ and   that can be distinguished and 
characterized by different biological roles (Table 1.1) [65].  
 
 
 
Table 1.1. Simplified overview of current understanding of the metabolic roles of the 3 PPAR 
isoforms. Adapted from Semple et al. 2006 [66]. 
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1.3.3.1. PPARα 
 
PPARα plays a crucial role in the control of lipid metabolism in response to nutritional, hormonal 
and environmental stimuli. It was described to be highly expressed in organs that carry out 
significant catabolism of fatty acids such as the liver, brown adipose tissue, heart, intestine and 
kidney [67, 68]. Therefore, identification of PPARα target genes has concentrated mainly on 
cellular lipid metabolism in the context of the hepatocyte. Indeed, the first PPARα target gene 
identified was acyl-coenzyme A oxidase [69] involved in fatty acid β-oxidation. Numerous genes 
involved in hepatic fatty acid oxidation were shown to be induced by PPAR α. Results from this 
group have been relevant for the identification and characterization of functional PPREs in key 
regulatory genes such as HMGCS2 (rate-limiting enzyme of ketogenesis); CPT1 and CPT2 
(involved in mitochondrial β-oxidation).  
 
PPARα can be activated by at least 2 different mechanisms. First, during fasting, the expression 
of PPARα in liver increases, an effect mediated by glucocorticoids that results in an increased 
amount of PPARα protein. Second the fatty acids that are liberated from the adipose tissue and 
travel to the liver may serve as ligands for PPARα. By means of such mechanism, the organism 
assures that the enzymatic system of the liver responds appropriately to the increased demands 
for fatty acid oxidation. 
 
 
1.3.3.2. PPAR 
 
PPAR is a master regulator for adipocyte differentiation [64, 70-72]. PPAR also regulates lipid 
metabolism, insulin sensitivity, cardiovascular disease, inflammation, organ development and 
tumor formation [73, 74]. PPAR has two isoforms, PPAR1 and PPAR2, which are created by 
alternative splicing [75]. PPAR1 is expressed in several tissues including liver, whereas 
PPAR2 is exclusively expressed in adipocytes, where it is key orchestrator of the cascade 
underlying adipocyte differentiation along with the CCAAT enhancer binding protein (C/EBP) 
[74]. The currently favored hypothesis is that C/EBP induces expression of PPAR, which 
provides the initial trigger for the adipogenic program [74]. 
PPAR also plays a key role in the switch of adipose tissue lipid metabolism to nutritional state. 
Its expression is highest postprandially [76] and its activation leads to the up-regulation of genes 
that mediate fatty acid up-take [77, 78]. PPAR may also promote a futile cycling in adypocytes 
between triglyceride esterification and de-esterification [79].  
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Given the central role of PPAR in the promotion of adipogenesis and the link between adiposity 
and insulin resistance, the discovery that PPAR is the target for the thiazolidinedione (TZD) 
antidiabetic drugs was unexpected [66].  In fact, several lines of evidence support the 
conclusion that TZDs exert their biological effects on insulin sensitivity through binding to 
PPAR (Figure 1.6).  
 
TZDs appear to coordinately activate gene expression leading to an increase in net lipid 
partitioning into adipocytes. Target genes directly regulated by PPAR that are involved in this 
pathway include lipoprotein lipase [77] and fatty-acid transport protein [80] which all favor 
adipocyte uptake of circulating fatty acids; phosphoenolpyruvate carboxykinase [81], glycerol 
kinase [79], which promote recycling rather than export of intracellular fatty acids. 
Together, these pathways lead to the net flux of fatty acids from the circulation and other tissues 
into adipocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. The insulin sensitization action of PPAR gamma. Adapted from Lehrke et al., 2005 
[73]. 
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1.3.4. Fsp27/CIDEC 
 
 
Fat specific protein 27 (FSP27) or cell death inducing DFF45-like effector C (CIDEC), the 
human homologue of FSP27 belong to the CIDE family [82, 83]. FSP27/CIDEC was described 
as an important regulator of energy homeostasis and its functions are closely linked to the 
development of metabolic disorders including obesity, diabetes and liver steatosis [72, 84]. 
 
The CIDE family consists into three isoforms: CIDEA, CIDEB and FSP27/CIDEC. CIDEA is 
highly expressed in brown adipose tissue and CIDEB in liver [82]. Regarding to the tissue 
distribution of FSP27/CIDEC it was described that it was highly and specifically expressed in 
brown and white adipose tissue [85]. Interestingly, FSP27 is also highly expressed in the fatty 
liver of typical diabetes or obese model ob/ob mouse and in the high fat-inducible fatty liver.  
 
In eukaryotic cells the excess of lipids are store in the white adipose tissue in lipid droplets.  
FSP27/CIDEC was identified as a new lipid droplet associated protein that was shown to be 
involved in the formation and modulation of the size of unicular lipid droplets through their 
protection from lipolysis and it is required for the efficient accumulation of triacylglycerols in 
mature adipocytes [85, 86].  
The expression of many adipocyte specific genes is affected by diettary manipulation. It was 
demonstrated that long-term intermittent fasting, significantly up-regulated FSP27 gene 
expression in WAT [86] and that PPAR2, C/EBPα, and insulin could be involved in its 
nutritional regulation.  
 
The role of FSP27 in promoting lipid droplet formation is not restricted to adipocytes. In fact, 
although FSP27/CIDEC is not expressed in normal liver, it was described to be highly 
expressed during hepatic steatosis since the excess of lipids stimulate the expression of lipid 
droplet associated proteins [72]. 
In hepatic steatosis, the expression of Fsp27/CIDEC is induced by proliferator-activated 
receptor  (PPAR). Serially deleted FSP27 luciferase reporter plasmids and chromatin 
immunoprecipitatation (ChIP) assays revealed the presence of a functional PPAR response 
element and direct binding of PPARto this element. Corroborating these findings, the 
expression of the mouse promoter FSP27 was markedly increase by the treatment with 
thiazolidinedione (TDZ), rosiglitazone – a specific ligand for PPAR. However, FSP27 was not 
activated by specific ligands of PPARα or PPARδ [72].  
 
Moreover, Matsusue and colleagues [72] have also demonstrated that repression of 
mitochondrial β-oxidation activity was associated with an increase in FSP27 expression. These 
data suggest that the accumulation of triglycerides and the increase of lipid droplets by FSP27 
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may be due to impaired β-oxidation activity and reduced triglyceride turnover. Whether how 
FSP27 suppresses β-oxidation activity remains unclear, however it was proposed that since 
FSP27 suppresses lipolysis there will be a lack of fatty acyl-CoA released from TG and this 
event will in turn impair mitochondrial β-oxidation. 
 
Recent data of this laboratory demonstrated that Hmgcs2, which regulates ketone body 
production, also regulates fatty acid oxidation [59]. Also, specific depletion of this enzyme 
correlates with 25% decrease in serum ketone bodies in fasted animals, and altered gene 
expression. By, microarray analysis (Table 1.2) it was showed that the gene most-up regulated 
in fasted animals when ketogenesis and FAO were blocked was FSP27/CIDEC. 
 
 
Table 1.2. Genes that are up regulated by HMGCS2 knock down. List of differentially expressed genes 
(up regulated >1.6 fold) in a microarray Affymetrix® (GeneChip Mouse Gene 1.0ST) performed with RNA 
of liver of shRNA control or shRNA Hmgcs2 treated mice (n=3). (Unpublished data from Haro D. and 
Marrero P., School of Pharmacy, University of Barcelona) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This finding prompted this group to further elucidate the role of FSP27/CIDEC during adaptation 
to fasting. It was demonstrated that during the early stages of fasting (<12-18h) FSP27 
expression was significantly increased (Figure 1.7A) and this expression decreased during the 
later phase of fasting (>12-18h) while Hmgcs2 and other FAO genes (Cpt1a, Cact, Cpt2), 
showed maximal expression (Figure 1.7B). At this point, the results suggested a kinetic 
mechanism of auto-regulation between short- and long-term fasting by which free fatty acids 
that arrive to the liver during early fasting are fated to accumulation/exportation by 
FSP27/CIDEC, while over longer periods of fasting the fatty acids are oxidized through the CPT 
system in mitochondria.  
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A B 
Figure 1.7. Hepatic Fsp27 expression is induced by early fasting.  
Mice fed Ad Libitum (AL) or subjected to 6h, 15h, or 24h fasting. (A) Fsp27, (B) Hmgcs2 and other fatty 
acid oxidation genes (Cpt1a, Cact and Cpt2) mRNA levels in liver. Results are means ± SEM for each 
group (n=5) ** P <0.01, *** P<0.001 relative to AL; # P<0.05, ## P <0.01 relative to 6h fast; ᵹᵹ P<0.01 
relative to 15h fasting. 
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1.4. Amino acid deprivation 
 
Mammals have evolved a wide range of adaptive mechanisms to detect and respond to 
fluctuations in dietary protein nutrients. At the level of individual cells, dietary protein limitation is 
manifested as amino acid deprivation, which activates an amino acid response (AAR) signal 
transduction pathway. Amino acid limitation regulates numerous steps in gene expression 
including chromatin structure, transcription start site, transcription rates, mRNA splicing and 
RNA export, turnover and translation  [87].  
 
Amino acid response pathway 
 
Limiting the extracellular supply of an essential amino acid or blocking the synthesis of an 
otherwise nonessential one results in an increase in uncharged tRNA that binds to and activates 
the general control nonderepressible protein 2 (GCN2) kinase. In this manner, the GCN2 
protein serves as a sensor of amino acid insufficiency. Thus depletion at the cellular level of any 
individual amino acid can trigger AAR. Once activated, GCN2 kinase phosphorylates the 
translation factor eIF-2α that suppresses general protein synthesis but promotes a paradoxical 
increase in translation of mRNA species. Among these are several activating transcription 
factors such as ATF4. ATF4 triggers increased transcription by binding to (CCACT-enhancer 
binding protein-activating transcription facto C/EBP-ATF response elements (CARE)), so named 
because they are composed of a half-site for the C/EBP family and a half-site for the ATF family 
transcription factors. The products of these CARE -containing genes modulate a wide spectrum 
of cellular events designed to adapt to dietary stress [88].  
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2. THESIS GOAL 
 
Currently, whereas the role of Fsp27/CIDEC begins to be better understood in adipose tissue, 
little is known about its physiology in liver. As discussed above, previous results of this group 
showed that the Fsp27/CIDEC gene expression is regulated in a time-dependent manner during 
fasting in liver, being induced in the early steps of fasting and decreased after a longer period.  
These previous results and the importance of Fsp27/CIDEC in regulating energy homeostasis, 
including its modulation by FAO prompted the present study where we aimed to further explore 
the physiologic role and to provide mechanistic insight of Fsp27/CIDEC regulation in adaptation 
to fasting response in HepG2 cells. We aimed to specifically answer two questions: 1) Why 
CIDEC expression decreases during prolonged fasting and 2) How FAO affects CIDEC 
expression. 
 
In the second part of the present study we aimed to elucidate if the mechanism by which Pgc-1α 
becomes activated in response to prolonged fasting and amino acid deprivation is somehow 
mediated by Foxa2. This notion is based in the suggestion that Foxa2 could be involved in the 
regulation of metabolic adaptation to low nutrient conditions such as fasting and amino acid 
deprivation in hepatocytes. This hypothesis, is further based in recent results of this group 
demonstrated that in these particular nutrient restriction conditions, both Foxa2 and Pgc-1α 
expression are increased in mice liver.  
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3. MATHERIALS AND METHODS  
 
3.1. Plasmid DNA preparation  
 
To obtain the plasmid DNA used in this study, the interest mouse promoters (Pgc-1α and 
Fsp27) were amplified by PCR, with Taq polymerase (Biotools), dNTPS, specific primers (see 
plasmid construct below) and mouse genomic DNA. The amplified product was run in an 
agarose gel to verify the product size. The band of interest was cut from the gel and purified 
with the Wizard SV Gel and PCR Clean System kit (Promega), according to the manufacturer’s 
instructions. 
After quantification of the purified product on NanoDrop-1000 (NanoDrop Technologies, Inc. 
Thermo Scientific) the product was inserted in a pGEM-T vector, according to the 
protocol pGEM-T and pGEM-T Easy Vector (Promega). 
The plasmid DNA was transformed into competent cells E.coli DH5α, previously prepared by 
salt washes (CaCl2) to permeabilize them, and frozen at -80
0
C, and then plated on indicator 
agar plates (AIX plates: 100 mg/L ampicillin, 8 mg/L IPTG, and 40 g/L XGal) for selection. 
The plates were incubated overnight at 37ºC; recombinants were selected by blue/white 
secreening on indicator plates. Positive white colonies are incapable to hydrolyze the substracte 
X-Gal because the insert causes the loss of the β-galactosidase activity, while colonies that 
have incorporated the empty vector (negative colonies) are blue due to the presence of the X- 
Gal hydrolysis products. The white positive colonies were left to grow overnight in 3 mL LB 
inoculums, with selection antibiotic (ampicillin). 
The plasmid DNA from inoculums was obtained with a commercial kit PureYield Plasmid 
Miniprep System (Promega). The plasmid DNA was sequenced (Macrogen sequencing 
service). 
After sequencing, the insert was released from pGEM-T, with restriction enzymes specific for 
the sequence amplified (see plasmid construct below), and ran in an agarose gel. The bands 
were purified (with the Wizard SV Gel and PCR Clean System kit (Promega)) and the insert was 
subcloned into the pGL3b vector. 
The plasmid DNA was transformed in competent cells E.coli DH5α and plated in agar plates 
with the selection antibiotic for pGL3b (ampicillin). Selection of positive colonies was performed 
through PCR screening. The DNA of the positive colonies selected was obtained with a 
commercial kit PureLink HiPure Plasmid Filter Maxiprep Kit (Invitrogen). 
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3.2. Plasmid construct and site directed mutagenesis 
3.2.1. Mouse PGC1-α promoter 
 
The PGC-1α promoter (nt -2010/-51 to the relative transcription start site) was amplified by PCR 
from mouse genomic DNA using Taq polymerase (Biotools) with the oligonucleotides forward 
(DH1384) and reverse (DH1385) containing the sequence of the restriction sites MluI and XhoI 
respectively (italicized and bolded in the primer sequence, see Primer Design, “Cloning” section 
in Annex). The PCR products were cloned in the vector pGEM-T and sequenced (Macrogen 
sequencing service). This plasmid was digested with MluI and XhoI and subcloned into the 
promoter firefly luciferase reporter gene vector pGL3-Basic (Promega). 
 
3.2.2. Mouse Fsp27 promoter  
 
The Fsp27 promoter (nt -2054/+18 to the relative transcription start site) was amplified by PCR 
from mouse genomic DNA using Taq polymerase (Biotools) with the oligonucleotides forward 
(DH1303) and reverse (DH1304) containing the sequence of the restriction sites MluI and XhoI 
respectively (italicized and bolded in the primer sequence see Primer Design, “Cloning” section 
in Annex). The PCR products were cloned in the vector pGEM-T and sequenced (Macrogen 
sequencing service). This plasmid was digested with MluI and XhoI and subcloned into the 
promoter firefly luciferase reporter gene vector pGL3-Basic (Promega). 
 
1.2.2.3. QuikChange™ Site-Directed Mutagenesis Kit 
 
The mutations in the CREB identified sequences in the mouse Fsp27 promoter were generated 
by site directed mutagenesis, carried out by a commercial kit - QuickChange
TM
Site-Directed 
Mutagenesis (Stratagene) following the manufacturer’s instructions. The mutants were 
generated by point mutations replacing the original sequences TGACTTCA (CRE1 site, -375/-
366) and CGTCA (CRE2 half site, -1792/-1787) by TGAGTATC and ATCGC respectively in 
both sense and antisense orientations, following the manufacturer’s instructions (see primer 
design, “Site direct mutagenesis” section in Annex). 
The QuikChange site-directed mutagenesis kit is used to make point mutations, switch amino 
acids, and delete or insert single or multiple amino acids. The QuikChange site-directed 
mutagenesis method is performed using PfuTurbo™ DNA polymerase ll and a thermal 
temperature cycler PfuTurbo DNA polymerase replicates both plasmid strands with high fidelity 
and without displacing the mutant oligonucleotide primers. The basic procedure utilizes a 
supercoiled double-stranded DNA (dsDNA) vector with an insert of interest and two synthetic 
oligonucleotide primers containing the desired mutation. The oligonucleotide primers, each 
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complementary to opposite strands of the vector, are extended during temperature cycling by 
using PfuTurbo DNA polymerase. Incorporation of the oligonucleotide primers generates a 
mutated plasmid containing staggered nicks. Following temperature cycling, the product is 
treated with Dpn I. The Dpn I endonuclease is specific for methylated and hemimethylated DNA 
and is used to digest the parental DNA template and to select for mutation-containing 
synthesized DNA.  
 
3.2.3. Automatic sequenciation of DNA 
 
The sequences and orientations of the constructions were verified by sequencing – Macrogen 
Inc. (Macrogen sequencing service). 
 
3.2.4. DNA oligonucleotide (primers) 
 
All DNA oligos were synthesized by Sigma-Aldrich with technology ultra-high base coupling 
efficiency, combined with optimized cartridge purification and 100% quality control by mass 
spectrometry (Designed primer sequences are listed in the Annex). 
 
3.3. Cell culture  
 
Cell Line Description Reference 
HepG2 Human liver carcinoma (Hommo sapiens) ATCC No. HB-8065 
 
HepG2 are adherent, epithelial-like cells growing as monolayers and in small aggregates. 
HepG2 cell line was derived from the liver tissue of fifteen year old male with differentiated 
hepatocelullar carcinoma. 
 
The human hepatocellular carcinoma cells HepG2 were cultured in Eagle's Minimum Essential 
Medium (MEM) supplemented with 4 mM glutamine, 100 μg/ml streptomycin sulfate, 100 
units/ml penicillin G, and 10% (v/v) fetal bovine serum (FBS). Cells were incubated at 37°C in 
humidified atmosphere containing 5% CO2. Culture medium was discarded and changed every 
2-3 days. To passage, cells were briefly washed twice with 1xPBS and 0.05% Trypsin-EDTA 
solution was added. The cell layer dispersed at 37°C for 5 min, trypsin was deactivated by 
adding complete growth medium. Cells were split 1:4 dilution every 5 days or counted (Trypan 
Blue stain method) and plated according the final experiment. Cells were replenished with fresh 
medium before all experiments. To induce the fasting response, cells were incubated for 16 
hours in a serum-free medium – Opti-MEM (Invitrogen) and supplemented with or without 10 
µM Etomoxir (6 hours); 10 µM Etomoxir plus 10 µM of GW9662 for 6 hours; 10 µM of Forskolin 
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(6 hours); 10 µM of Forskolin (6 hours) and pretreatment with 50 µM of H89 (1 hour); 10 µM of 
Wy14643 (24 hours). In the controls of these experiments, cells were also incubated for 16h in 
Opti-MEM (Invitrogen) and the vehicles (water or DMSO) of the specific reagents used in each 
experiment were added – see “Reagents used in cell culture specific treatments” below. 
 
3.4. Reagents 
3.4.1. Reagents used in cell culture maintenance 
 
Regent Reference 
Minimum Essential Media (MEM) GIBCO, 61100-087 
Fetal Bovine Serum (FBS) GIBCO, 10270-106 
Pen Strep (Penicillin-Streptomycin) GIBCO, 15140-122 
L-Glutamine 200mM GIBCO, 25030-024 
Sodium bicarbonate solution 7.5% GIBCO, 15140-122 
OPTI-MEM® I GIBCO, 31985-047 
Tripsin-EDTA 10X GIBCO, 15400-054 
 
 
3.4.2. Reagents used in cell culture specific treatments 
 
Reagent Reference Description Vehicle 
GW9662 Sigma M6191 PPAR antagonist Dissolved in DMSO to 10 mM. 
ETOMOXIR Sigma E1905 CPT1 inhibitor Dissolved in water to 10 mM. 
FORSKOLIN 
H89 
Wy14643 
Sigma F6886 
Sigma B1427 
Sigma C7081 
cAMP agonist 
PKA inhibitor 
PPARα agonist  
Dissolved in DMSO to 10 mM. 
Dissolved in water to 10 mM. 
Dissolved in DMSO to 10 mM. 
 
Following reconstitution stock solutions aliquots were stored at -20°C. 
 
 
3.4.3. Reagents used in cell culture transfection 
 
Reagent Reference 
Lipofectamine LTX Reagent Invitrogen, 15338-100 
DharmaFECT®4 Transfection Reagent Thermo Scientific, T-2004-01 
 
 
3.5. Transient transfection and gene reporter assays 
 
HepG2 cells were plated at a density of 1.5 x 10
5 
cells/well on 24-well plates and cultured for 
24h in culture medium (MEM). Cells were transiently transfected using Lipofectamine LTX 
(Invitrogen) at a ratio of 2.5 µl to 1 µg of DNA, following the manufacturer’s instructions. For 
each transfection 0.4 μg of reporter gene construct (pGL3b-Fsp27 or pGL3b-Pgc-1α) and 
different amounts of the transcription factors expression vectors (pcDNA3, CREB or FOXA2) 
were co-transfected (indicated in the respective graphs). The plasmid pRL-CMV (10ng/well) was 
included as an internal transfection control. The total amount of transfected DNA was kept 
constant among experimental groups by the addition of pcDNA3 empty plasmid. 
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At approximately 48 h following transfection, cellular extracts were prepared for analysis of 
luciferase activity, by washing the cells with phosphate-buffered saline (PBS 1x), and harvested 
in 100 μl of 1x Passive lysis buffer (E194A, Promega). The lysates were collected and a 10 μl 
aliquot was used for Firefly luciferase assays using the Dual-Luciferase Reporter Assay System 
(E1960, Promega). Firefly and Renilla luciferase activities were dertermined in a Berthold Sirius 
Luminometer. Relative luciferase activity was given as the ratio of relative luciferase unit/relative 
Renilla unit. 
 
3.6. siRNA Transfection 
 
Specific human SIRT1 (T2004-01) and siControl nontargeting (D-001210-01) siRNAs were 
purchased from Dharmacon (Thermo Fisher). HepG2 cells were seeded in 6 well plates at 
density 4.5 x 10
5 
cell/well in MEM and grown for 24h. Transfection was performed according to 
the instructions of Dharmacon using 5 µl of DharmaFECT®4 and 25 nM per well final siRNA 
concentration. At 72h following transfection, cells were rinsed with PBS, and total RNA was 
isolated and analyzed by real time PCR. 
 
3.7. KCREB Transfection – Fluorescence assay 
 
HepG2 cells were seeded in 6 well plates at density 4.5 x 10
5 
cell/well in MEM and grown for 
24h. Cells were transiently transfected using Lipofectamine LTX (Invitrogen) at a ratio of 2.5 µl 
to 1 µg of DNA, following the manufacturer’s instructions. The constructs GFP (500 ng) and 
pcDNA3-KCREB (500 ng) were co-transfected. The experiment controls only contained the 
GFP construct transfected. At 24h following transfection, cells were visualized and 
photographed with a confocal laser microscope LEICA DMI 4000 B in order to access 
transfection efficiency. Cells were then incubated for 16 hours (overnight) in a serum-free 
medium – Opti-MEM (Invitrogen) and then treated for 6h with 10 µM of forskolin and controls 
were supplemented with vehicle (DMSO). Following the 6h forskolin treatment, cells were rinsed 
with PBS, and total RNA was isolated and analyzed by real time PCR. 
 
3.8. Isolation and analysis of RNA 
3.8.1. Isolation of total RNA 
 
Total RNA was extracted from HepG2 cells using TRI Reagent Solution (Ambion) according to 
manufacturer’s instructions. Cultured cells were washed twice with cold PBS 1x and isolated by 
scrapping. TRI Reagent maintains the integrity of the RNA due to highly effective inhibition of 
RNAse activity while disrupting cells and dissolving cell components during sample 
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homogenization. Furthermore, this reagent is free of protein and DNA contamination. However, 
RNA was pretreated with DNaseI (Ambion) to eliminate genomic DNA contamination.  
RNA was dissolved in DEPC-treated water (Sigma-Aldrich) and the concentration and purity of 
each sample was obtained from A260/A280 and A260/230 measurements in a micro-volume 
spectrophotometer NanoDrop-1000 (NanoDrop Technologies, Inc. Thermo Scientific). 
 
3.8.2.  RT-PCR 
 
Reverse transcription polymerase chain reaction is used to synthetized cDNA from one 
microgram of total RNA. Total RNA was reversed transcribed using random hexamers (Roche 
Diagnostics), dNTPs (Attend Bio) and M-MLV reverse transcriptase (Invitrogen) following 
manufacturer’s instructions.   
 
3.8.3. Real time PCR 
 
cDNA was subjected to real time PCR analysis using TaqMan universal PCR master mix 
(Invitrogen) and the specific gene expression Taqman probes from Applied Biosystems and 
normalized against those of 18S ribosomal RNA determined by Eukaryotic 18S rRNA 
endogenous control (Applied Biosystems). The following human gene probes were used: 
CIDEC Hs00535723_m1, PEPCK Hs00159918_m1, PGC-1α Mm00447181_m1, FOXA2. 
Reactions were measured in duplicate. The reactions were performed in ABI PRISM® 7700 
Sequence detection Systems (Applied Biosystems) in 96-well plates. The thermal cycling 
conditions were, an initial activation step for 2 min at 50 °C and 10 min at 95 °C and 40 cycles 
of melting ate 95 °C for 15 sec and annealing/extend for 1 min ate 60 °C [89]. 
Results were obtained by the comparative Ct method and expressed as fold of the experimental 
control. The comparative CT (ΔΔCt) method [90] was used to determine the relative target 
quantity in the samples. 
 
3.9. Statistical analysis  
 
Results are expressed as means ± standard error mean (SEM) from n=2 to n=6. The statistical 
significance of differences found between groups was assessed by one-way analysis of 
variance. An unpaired Student’s t test was use to compare the groups. P<0.05 was considered 
as statistically significant difference.  
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3.10. Information technologic tools 
 
Entrez-Pubmed, National Center for Biotechnology Information (NCBI, USA): 
http://www.ncbi.nlm.nih.gov/pubmed/ 
TFSEARCH: Searching Transcription Factor Binding Sites: 
http://www.cbrc.jp/research/db/TFSEARCH.html 
 
3.11. Additional Information 
 
Any missing information regarding the experimental procedures, which also cannot be found in 
Annex, means that the procedure was performed according to the detailed information given by 
“Molecular Cloning, a Laboratory Manual” (Sambrook, Fritsch and Maniatis), or following the 
protocols provided in the instructions of the commercial kits used. 
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4. RESULTS 
 
4.1. Down regulation of FAO increases CIDEC expression. 
 
To elucidate whether the FAO rate affected CIDEC expression, we have treated HepG2 cells 
with 10 µM of etomoxir (amount previously optimized), a CPT1 inhibitor that represses FAO 
[91]. Figure 4.1A shows that this treatment significantly increased, approximately six-fold, 
CIDEC (left panel) and PEPCK (right panel) mRNA levels in HepG2 cells when compared to the 
control. 
 
Figure 4.1. CIDEC is induced by etomoxir.  
(A) CIDEC (left panel) and PEPCK (right panel) mRNA levels in HepG2 cells, serum-starved for 16 h 
and treated with 10 µM of etomoxir for an additional 6 h. (B) Effect of synthetic PPAR antagonist 
(GW9662) in CIDEC expression. CIDEC (left panel) and PEPCK (right panel) mRNA levels in HepG2 
cells, serum-starved for 16 h and treated with 10 µM of etomoxir and with or without 10 µM of GW9662 
(6 hours). Results are means ± SEM of three independent measurements. ***, P<0.001, relative to 
control (HepG2 cells treated with vehicle - DMSO); ##, P<0.01 relative to the etomoxir treatment. 
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Previously it was suggested that impairment of FAO leads to triacylglyceride accumulation that 
stimulates lipid droplet associated proteins like Fsp27/CIDEC and that this mechanism was 
specifically mediated by PPAR[64, 72]. 
Having this into account and to further study whether PPARwas involved in Fsp27/CIDEC 
expression changes affected by FAO rate, we used a specific PPARantagonist (GW9662). As 
shown in Figure 4.1B, treatment of HepG2 cells with 10 µM of GW9662 had no effect on CIDEC 
expression (left panel) while the same treatment resulted in a significant reduction of PEPCK 
expression (right panel). PEPCK was used as a positive control for these experiments since it 
has been described as a direct target of PPAR [92]. 
These data suggest that CIDEC expression is regulated by mitochondrial FAO rate, but the 
mechanism by which CIDEC is upregulated when FAO is impaired is not mediated by PPAR.   
 
 
 
4.2. The induction of CIDEC expression is not mediated by PPARα during fasting. 
 
Under physiological conditions, the function of PPARα is mainly evoked during fasting, which is 
associated with increased hepatic PPARα mRNA expression and increased FFA levels that are 
natural ligands of PPARα [93]. Based on this data, we investigated whether it could be one of 
the signals triggering the induction of CIDEC in fasting conditions. Figure 4.2 shows that CIDEC 
expression (left panel) is unchanged upon treatment with 10 µM of specific PPARα ligand 
Wy14643 (Sigma) while, under the same conditions, HMGCS2 mRNA levels (right panel) were 
significantly increased in HepG2 cells, as expected, since HMGCS2 is a target gene of PPARα 
[59]. 
These results suggest that the fasting expression pattern of CIDEC is not modulated by the 
activity of PPARα in HepG2 cells. 
 
 
 
 
 
35 
 
 
 
4.3. Fsp27 is activated by CREB and its induction by fasting is repressed by SIRT1. 
 
The liver contributes to glucose homeostasis by promoting either storage or production of 
glucose depending on the physiological state. During early fasting, the increase in circulating 
pancreatic glucagon stimulates the gluconeogenic program through the activation of the cAMP 
pathway leading to the upregulation of gluconeogenic genes [9, 13, 34].  
To further investigate the expression pattern of Fsp27/CIDEC during adaptation to fasting 
response we treated HepG2 cells with 10 µM of forskolin (amount previously optimized), an 
adenilate cyclase activator which leads to an increase of intracellular levels of cAMP. Figure 
4.3A shows that CIDEC (left panel) is markedly induced by forskolin treatment as well as 
PEPCK (right panel) that shows the expected effect of this cAMP stimulator.  
Cyclic AMP (cAMP) regulates the expression of numerous gluconeogenic genes through 
phosphorylation of CREB, mediated by protein kinase A (PKA) [9]. To further establish that the 
induction of CIDEC expression is regulated by the cAMP-mediated activation of CREB activity, 
corroborating the specificity of the forskolin treatment, we repeated the forskolin experiment with 
the addition of a protein kinase A (PKA) inhibitor, H89 (Figure 4.3B). In the presence of the PKA 
inhibitor H89, CIDEC expression was decreased approximately two-fold when compared to 
forskolin induction (Figure 4.3B, left panel). As expected, PEPCK (Figure 4.3B, right panel) 
expression was markedly diminished, approximately eight-fold, by the addition of H89.  
Figure 4.2. Effect of specific PPARα agonist (Wy14643) in CIDEC expression. 
CIDEC (left panel) and HMGCS2 (right panel) mRNA levels in HepG2 cells treated with 10 µM of  
Wy14643 (Sigma) for 24 hours. Results are means of two independent experiments. **, P<0.01 relative to 
control (HepG2 cells treated with vehicle - DMSO). 
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A 
Figure 4.3. CIDEC is induced by Forskolin and repressed by PKA inhibitor H89.  
(A) CIDEC (left panel) and PEPCK (right panel) mRNA levels in HepG2 cells treated with 10 µM of forskolin in 
OPTI-MEM (Invitrogen) for  6 h (mean of three independent experiments). (B) The effect of treatment with 
forskolin 10 µM for 6h and/or pretreatment with H89 (50 µM) for 1 hour in CIDEC (left panel) and PEPCK 
(right panel) mRNA levels in HepG2 cells. Cells were in OPTI-MEM (Invitrogen), or vehicle (DMSO). Data 
represent the means ± SEM of three independent experiments. **, P<0.01; ***, P<0.001, relative to the 
control; ##, P<0.01, ###, P<0.001 relative to forskolin activation of CIDEC and PEPCK mRNA levels. 
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To further support these data and to provide additional information for the mechanism regulating 
CIDEC expression in the adaptation to fasting, a vector containing a dominant repressor of 
CREB activity  – KCREB expression vector – was transfected in HepG2 cells and treated with 
10 µM of forskolin, the transfection was followed by visible fluorescence from a co-expressed 
green fluorescent protein (GFP). Although not very efficient, about 20% (Figure 4.4A), the 
transfection of KCREB expression vector significantly decreased the induction of CIDEC mRNA 
levels by cAMP (Figure 4.4B, left panel). PEPCK expression, as expected, was also decreased 
in the presence of dominant negative of CREB expression vector relatively to the forskolin 
induction (Figure 4.4B, right panel).  
 
 
 
 
 
 
 
 
Figure 4.4. CIDEC is induced by Forskolin and repressed by a negative dominant of CREB – KCREB.  
(A) HepG2 appearance (left panel) and transfection assessment in HepG2 cells by green fluorescence 
protein (GFP) (right panel). (B) CIDEC (left panel) and PEPCK (right panel) mRNA levels in HepG2 cells 
transfected with GFP (green fluorescent protein), or GFP plus KCREB (500 ng) expression vector and 
treated with 10 µM of Forskolin (in OPTI-MEM - Invitrogen) for 6h.  Data represent the means ± SEM of 
three independent experiments. ***, P<0.001, relative to the control; #, P<0.05, relative to forskolin activation 
of CIDEC and PEPCK mRNA levels. 
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To elucidate the molecular mechanism underlying Fsp27/CIDEC fasting mediated expression in 
HepG2 cells and in liver, the transcriptional regulation of Fsp27 through CREB was 
investigated. 
By searching the TFSEARCH database (http://www.cbrc.jp), two putative CREB response 
elements (CRE) in the 5’-flanking region of the mouse Fsp27 gene (nt -2054/+18 relative to the 
transcriptional start site) were revealed at positions -1787/-1792 (CRE2) and -366/-375 (CRE1) 
from the transcription start site (Figure 4.5A). 
The upstream site (CRE2) is a conserved half-site motif (CGTCA) while the downstream site 
(CRE1) is an eight-base-pair element (TGACTTCA) partially conserved from the canonical 
palindrome (TGACGTCA).  
To elucidate whether the Fsp27 gene was induced by CREB, reporter gene transfection studies 
were carried out. Several constructs were produced with the luciferase gene as a reporter and 
transfected in HepG2 cells (Figure 4.5B). The same cells were co-transfected with an 
expression vector for CREB. Figure 4.5C, shows that CREB expression significantly induced 
(thirty-fold) the wild type reporter and this induction was diminished when single CREs were 
mutated (mut 1 or in a higher extend mut 2) or completely abolished, when both elements were 
simultaneously mutated (mut x2).  These results identify the sequences CRE1 and CRE2 as 
CREB responsive elements in Fsp27 mouse gene.  
Taken together, these data support that CIDEC is a direct target of CREB activity in 
hepatocytes and this process is mediated by the cAMP axis activation during the early fasting 
state.  
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CGTC
A 
TGACTTCA 
atcgc 
TGAgTatc 
TGACTTCA 
TGAgTatc atcgc 
CGTC
A 
CGTCA TGACTTCA 
-1792 -1787 - 375 - 366 
-2054 +18 
Figure 4.5. Fsp27 mouse promoter activity is induced by CREB transcription factor. 
(A) 5’-flanking region of the mouse Fsp27 gene with the nucleotide sequences of the putative CREB sites 
- CRE1 and CRE2. (B) The subsequent constructs have the correspondent mutated elements inside the 
boxes bellow the wild type construct. The original sequence is shown as a line. (C) HepG2 cells 
transfected for 48 h with Fsp27 promoter constructs cloned in pGL3basic and co-transfected with either 
pcDNA3 or pcDNA3-CREB (150 ng) expression vectors. Results are represented by fold activation to the 
WT promoter construct. pGL3basic activation was subtracted from each condition. Data represent the 
means ± SEM of four independent experiments performed in duplicate. *, P<0.05; **, P<0.01; relative to wt 
construct; #, P<0.05, ##; P<0.01 relative to CREB activation of WT promoter. 
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Once gluconeogenic gene expression is activated, the nutrient-sensing deacetylase SIRT1 
reaches a maximal activity promoting a fasting-inducible switch between the early and late 
signaling programs [13]. Having this into account, and to elucidate the role of increased levels of 
SIRT1 in the regulation of CIDEC during fasting adaptation, SIRT1 activity was disrupted by 
siRNA in HepG2 cells. Figure 4.6 shows that CIDEC mRNA expression was induced by siRNA 
mediated down-regulation of SIRT1, which suggests that SIRT1 activity could repress the 
expression of CIDEC during the fasting-inducible switch. Furthermore, arguing in this favor, 
previous findings of this group, showed that CIDEC expression is decreased during the late 
phase of fasting, coincident with the increased levels of SIRT1. 
 
 
Figure 4.6. CIDEC is induced by SIRT1 depletion. 
CIDEC mRNA levels in HepG2 cells treated with siRNA control or siRNA of SIRT1. Data represent the 
means ± SEM of three independent experiments. *, P<0.05 relative to the siRNA control. 
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4.4. Effect of fasting and amino acid deprivation in PGC-1α expression. 
 
During late fasting, glucagon effects are attenuated, CRTC2 is down-regulated due to SIRT1-
mediated deacetylation and its contribution to the fasting co-transcriptional response is 
significantly diminished [15]. The maintenance of gluconeogenic response through prolonged 
fasting is mediated by FOXO1 and PGC-1α [13, 34]. In fact, PGC-1α co-transcriptional activity is 
important for the compensatory metabolic responses that occur during food deprivation [15]. 
Previous results of this group showed an interesting expression pattern of Pgc-1α in response 
to dietary manipulations in mice such as fasting and amino acid deprivation (leucin deprived 
diet). Figure 4.7A shows that hepatic levels of Pgc-1α of mice subjected to a leucin deprived 
diet (Ad Libitum (-) leu) were unchanged, whereas under fasting conditions hepatic levels of 
Pgc-1α were significantly increased, as expected. Interestingly, in livers of fasted mice 
previously treated with a leucin deprived-diet Pgc-1α is induced more than 15-fold. 
In these conditions of limit nutrient availability, a complex gene network functions to maintain 
whole body homeostasis of metabolites such glucose and amino acids. One of these genes is 
FOXA (forkhead box A) family. Recently, was described that this gene mediates the induction of 
Pepck in fasting conditions [42] and also that Foxa2 expression is induced upon amino acid 
deprivation [45].  So, to explore the mechanism mediating the significant increase of hepatic 
Pgc-1α levels in response to fasting and to a leucine deprivation we studied the gene 
expression of Foxa2 in the same animals. Figure 4.7B shows that liver of fasted animals 
previous treated with a leucin deprived diet significantly enhanced Foxa2 expression.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Pgc-1α and Foxa2 are induced upon leucin deprived diet in fasting conditions. 
(A) Pgc-1α mRNA levels and (B) Foxa2 mRNA levels in liver of mice fed Ad Libitum (Ad Libitum Control), 
fed with a leucin deprived diet (Ad Libitum (-) leu, fasted (Fast control) or fasted and previously subjected to 
a leucin deprived diet (Fast (-) leu). Results represent the means ± SEM of six independent experiments. *, 
P<0.05; **, P<0.01; relative to the Ad Libitum control group; # P<0.05 relative to the fast control group. 
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These data, and previous findings suggesting that the genes that regulate hepatic response are 
blunted in the absence of Foxa2 [42], prompted us to elucidate if Foxa2 was mediating the Pgc-
1α induction observed during fasting and amino acid deprivation (Figure 4.7A). Towards this 
end, Pgc-1α mouse promoter was cloned (nt -2010/-51 to the relative transcription start site) in 
a plasmid which drives the expression of a luciferase reporter gene (pGL3b) and, reporter gene 
transfection studies were carried out. Since previous studies suggested that Foxa2 allows 
chromatin access for hormone dependent transcription factors that are activated during food 
deprivation [42], we transfected HepG2 cells with either Pepck or Pgc-1α promoters and 
different concentrations of expression vectors for CREB and FOXA2 (indicated in the graph). 
Figure 4.8 shows that CREB expression significantly induced both Pepck (left panel) and Pgc-
1α (right panel) promoters, while single addition of FOXA2 had no effect in the activity of the 
promoters. Then, when co-tranfected with CREB and FOXA2 both Pepck and Pgc-1α promoter 
activities were induced however in a lesser extend then the activation observed for CREB itself.  
These results suggest that indeed Foxa2 plays a role in the hepatic response in the adaptation 
to amino acid deprivation and fasting although the mechanism by which Foxa2 is mediating this 
response is not by allowing CREB binding to both Pepck and Pgc-1α promoters in HepG2 cells.  
 
Figure 4.8. Pgc-1α and Pepck promoter activities are induced by CREB but not by FOXA2 
transcription factors. 
Transient assay of HepG2 cells transfected for 48 h with pGL3b (control) or the Pgc-1α and Pepck 
promoters and co-transfected with either pcDNA3 and/or pcDNA3-CREB, pcDNA3 and/or pcDNA3-
FOXA2 or pcDNA3-CREB plus pcDNA3-FOXA2 expression vectors, represented by fold activation to 
pGL3b. pGL3b activation was subtracted from each condition. Data represent the means ± SEM of three 
independent experiments performed in duplicate. **, P<0.01 relative to pcDNA3. 
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5. DISCUTION 
 
 
Fat specific protein of 27 kDa (FSP27) or the cell death-inducing DNA fragmentation factor 45-
like effector C (CIDEC, the human homologue of FSP27) belong to the CIDE family [83, 84]. 
The FSP27 was previously reported to be a lipid droplet-associated protein [84-86], which is 
expressed in white adipose tissue (WAT) [85, 86] or in steatotic liver [72]. Moreover, as previous 
described, results of this group showed that Fsp27/CIDEC expression was induced in fasting 
liver.   
 
The previous findings prompted us to further investigate the mechanism by which Fsp27/CIDEC 
is mediating fasting adaptation and regulated by FAO rate in liver. Towards this end, we use an 
in vitro model – the assays were carried out in a human liver carcinoma cell line, HepG2 – 
where the fasting condition was mimed by serum-starvation of cultured cells. 
It was described that Fsp27 expression in hepatocytes significantly decreases the activity of 
mitochondrial β-oxidation and reduces triglyceride turnover [72, 84]. The present study showed 
that pharmacological inhibition of FAO (etomoxir, Figure 4.1A) in HepG2 cells induces CIDEC 
expression. This data suggests a direct link between impaired FAO and CIDEC induced 
expression. However, the mechanism mediating this link is not so clear.   
Previously it was suggested that an impairment in FAO leads to triglyceride accumulation which 
stimulates lipid droplet-associated proteins such as FSP27/CIDEC and also that this TG 
accumulation mediated by Fsp27 gene is specifically regulated by PPAR and its specific 
ligands [72, 75]. This data prompted us to speculate that the missing link between induction of 
CIDEC and FAO inhibition could be mediated by PPAR. However, analysis of CIDEC mRNA 
levels in HepG2 cells treated simultaneously with etomoxir and GW9662, an antagonist of 
PPAR (Figure 4.1B) didn’t show any effect in CIDEC expression. This data suggests that 
inhibition of FAO could alter gene expression through a different mechanism from that of 
increased levels of free fatty acids, which are natural ligands of the PPARs.  
Regarding, to the induction of Fsp27 during fasting, the data present in this study suggests that 
PPARα, a master regulator of fasting liver [65], is not one of the signals triggering this induction 
(Figure 4.2). In accordance with these findings,  a previous report showed that Fsp27 promoter 
is not activated by ligands of PPARα nor PPAR δ [72]. Also, these results are corroborated by a 
preceding suggesting that induction of CIDEC was not mediated by PPARα [94]. 
Interestingly, CIDEC gene expression was up regulated by forskolin a cAMP agonist in HepG2 
cells (Figure 4.3A). Consistently, mouse Fsp27 promoter was induced approximately 30-fold by 
CREB. Indeed, the present study demonstrates two function CRE binding sites that directly 
interact with CREB in vitro. These results suggest that Fsp27/CIDEC could be direct target of 
hepatic CREB. To demonstrate additional evidence for this mechanism and to prove the 
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specificity of forskolin treatment we showed that impairment of PKA (by its inhibitor H89) 
resulted in the decrease of CIDEC mRNA levels, suggesting that indeed forskolin is inducing 
CREB activity and in turn CREB is activating CIDEC.  Furthermore, the effect of KCREB 
expression vector (Figure 4.4B) confirms that Fsp27/CIDEC is a direct target of CREB in HepG2 
cells.  
CIDEC mRNA levels were increased in HepG2 cells when SIRT1 activity was impaired by 
siRNA. Recently, it has been suggested a switch from early gene activation via CRTC2 to late 
activation of FOXO1 being critical for transcriptional regulation in fasting [13]. CRTC2 is a 
coactivator responsible for CREB-mediated transcriptional activation of the hepatic 
gluconeogenic program [11, 12]. However, it has also been proposed that the transcriptional 
response to fasting is only transiently dependent on CRTC2 with the demonstration that it is 
deacetylated by the NAD
+
 dependent enzyme SIRT1 which allows its ubiquitination and 
degradation in proteasome after long term fasting, suppressing CREB-CRTC2 signaling [95]. 
These data, together with the previous results demonstrating that Fsp27 is induced in early 
fasting, fit with the model suggested by Liu et al. [13] in which CREB mediated expression is 
attenuated in long fasting periods. 
Also, SIRT1 regulation seems to be the missing link that could explain the induced expression 
of CIDEC when FAO is impaired (Figure 4.1). Recently SIRT1 has been suggested has a link 
between protein acetylation and metabolism [17]. Vilà-Brau et al., [59] suggested a feed-forward 
mechanism in which the oxidative metabolism (FAO and ketogenesis), through NADH and ATP 
supply, would be expected to pull forward an anabolic process like gluconeogenesis, that would 
in turn generate NAD
+
 and stimulate SIRT1 (a NAD
+
 consuming enzyme) activity. Arguing in 
favor of this hypothesis, and validating our model, it was described that inhibition of 
mitochondrial fatty acid oxidation with etomoxir, the CPT1 inhibitor used in the experiments 
present in this study, decreases the NAD
+
/NADH ratio [96]. Therefore, once Fsp27/CIDEC is a 
gene that is repressed by SIRT1 (Figure 4.6) will be up regulated by an impaired FAO. 
Our results argue for a model of temporal regulation of Fsp27/CIDEC expression in response to 
fasting adaptation and FAO rate (Figure 5.1).  
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Figure  5.1.  Temporal regulation of Fsp27/CIDEC expression in response to fasting adaptation and 
FAO rate.At the onset of fasting glucagon circulating levels are increased and insulin levels decreased. 
This hormonal change produces an increase in both the levels and activity of the transcriptional 
coactivator CRTC2, which by activating CREB increases the expression of hepatic Fsp27/CIDEC. With 
sustained fasting (>12-18h) SIRT1 becomes activated and deacetylates CRTC2. This event allows the 
ubiquitination of the protein targeting it for degradation. Furthermore, these conditions promote the 
switching to the utilization of free fatty acids and thereby FAO rate increases. This increment results in the 
increase of NAD
+
/NADH ratio which will further activate SIRT1 (a NAD
+
 consuming enzyme activity).   The 
activation of SIRT1 results in an impairment of CIDEC expression. SIRT1 activation also outcomes the 
deacetylation of FOXO1 and its coactivator PGC-1α which is associated with an increase in their activities, 
providing a further mechanism for gluconeogenesis maintenance in response to prolonged fasting. 
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Effect of fasting and amino acid deprivation in PGC-1α expression. 
 
Survival during prolonged food deprivation depends on the activation of hepatic 
gluconeogenesis which is mediated by the cAMP response element binding protein (CREB). As 
discussed above, in the late fasting state, the maintenance of gluconeogenic response through 
prolonged food deprivation conditions is mediated by FOXO1 and PGC-1α [13]. Accordingly, 
Figure 4.7A shows that PGC-1α expression is increased in livers of mice subjected to prolonged 
fasting conditions. Interestingly this increase is even higher (15-fold) when the same animals 
are previously treated with a leucin deprived diet. 
Also, these conditions induced Foxa2 mRNA levels (Figure 4.7B). It was previously  suggested 
that Foxa2 is required for activation of hepatic gluconeogenic program during fasting [42]  by 
cAMP and glucocorticoids once it allows chromatin access for hormone-dependent transcription 
factors that are activated during the fasting response [42, 97, 98]. This notion is based on the 
aforementioned proximity of Foxa2 binding sites to CREs and GREs in cis-regulatory elements 
of several gluconeogenic genes [99, 100]. Also, it has been reported that Foxa2 increases the 
efficacy of CREB binding to Pepck promoter [42].  
Having this into account, and a previous report showing that Foxa2 expression was induced 
upon amino acid restriction [45] we speculated that the induction of Pgc-1α expression 
observed in both fasting and amino acid deprived conditions would be mediated by Foxa2 
activity, since under these two dietary manipulations there were be more Foxa2 available which 
would increase and facilitate the binding of CREB to the promoter.  
The transient assays performed in HepG2 cells confirmed that both Pepck and Pgc-1α 
promoters are indeed direct targets of CREB [9] but, when co-transfected along with FOXA2 the 
induction was not significant (Figure 4.8) suggesting that Foxa2 is not facilitating the binding of 
CREB to the promoters. These data did not confirm the previous findings described by Zhang et 
al., [42] or other reports that identified a Foxa binding site in Pepck promoter [99, 101]. 
Contrarily, corroborating our results, Wolfrum et al., [43] reported that Foxa2 did not bind to the 
conserve Hnf3/Foxa site in the Pepck promoter, suggesting that Pepck promoter is not a target 
of Foxa2 in fasting conditions.  
Our results of induction of Pgc-1α and Foxa2 gene expression in fasting and amino-acid 
deprived conditions are supported by other findings implicating Pgc-1α and Foxa2 in the 
adaptation of gluconeogenic genes during food deprivation conditions [15, 42, 45]. Still, the 
transient assays in HepG2 cells suggested that Foxa2 is not mediating the CREB targeting to 
the Pgc-1α neither the Pepck promoters. These results suggest that this is not the mechanism 
by which Foxa2 is regulating the activation of the hepatic transcriptional program of 
gluconeogenesis during adaptation to limit food supply.  
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6. CONCLUSIONS 
 
To conclude, in the first part of this study we showed that a lipid droplet-associated protein, 
Fsp27/CIDEC, was expressed in HepG2 cells in a physiological situation like fasting and that 
this induction was not mediated by PPARα.  
This study provides significant mechanistic advance for the regulation of Fsp27/CIDEC in 
adaptation to fasting response in HepG2 cells, since we demonstrated that Fsp27/CIDEC is a 
CREB target gene (positively regulated by the PKA-CREB-CRTC2 pathway) that could be up-
regulated when FAO is impaired and that the fluctuations in SIRT1 activity, in response to 
nutrient availability, mediate this mechanism.  
In the second part of this study, we showed that Pgc-1α and Foxa2 expression are increased in 
livers of mice subjected to prolonged fasting and previously treated with a leucin deprived diet. 
Further we show that under our experimental conditions the activation of the hepatic 
transcriptional program of gluconeogenesis during adaptation to limit food supply (fasting and 
amino acid deprivation) appears not to be regulated by the recruitment of CREB by Foxa2 for 
the Pgc-1 or the Pepck promoters. 
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8. ANNEX 
 
8.1. Vectors 
8.1.2. Cloning vectors 
 
pGEM®-T Vector 
The pGEM®-T Vector Systems are convenient systems for the cloning of PCR products.  
T-overhangs for Easy PCR Cloning: This vector is a linearized vector with a single 3´-terminal 
thymidine at both ends. The T-overhangs at the insertion site greatly improve the efficiency of 
ligation of PCR products by preventing recircularization of the vector and providing a compatible 
overhang for PCR products generated by certain thermostable polymerases. 
 
Blue/White Selection of Recombinantes: T7 and SP6 RNA polymerase promoters flank a 
multiple cloning region within the α-peptide coding region of the enzyme β-galactosidase. 
Insertional inactivation of the α-peptide allows identification of recombinants by blue/white 
screening on indicator plates (AIX plates: 100mg/L ampicilin, 8mg/L IPTG, and 40mg/L XGal). 
Choice of Restriction Sites for Release of Insert: The pGEM®-T vector contains numerous 
restriction sites within the multiple cloning region.  
 
8.1.3. Promoter vectors 
 
The Reporter Vectors provide a basis for the quantitative analysis of factors that potentially 
regulate mammalian gene expression. The backbone of the Reporter Vectors is designed for 
increased expression, and contains a modified coding region for firefly (Photinus pyralis) 
luciferase that has been optimized for monitoring transcriptional activity in transfected 
eukaryotic cells. 
 
 
pGL3-Basic Vector 
 
The pGL3-Basic Vector (Promega, Ref. E1751) lacks eukaryotic promoter and enhancer 
sequences, allowing maximum flexibility in cloning putative regulatory sequences. Expression of 
luciferase activity in cells transfected with this plasmid depends on insertion and proper 
orientation of a functional promoter upstream from luc+. Potential enhancer elements can also 
be inserted upstream of the promoter or in the BamHI or SalI sites downstream of the luc+ 
gene. 
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pRL-CMV Vector 
The pRL Reporter Vectors contain a cDNA (Rluc) encoding Renilla luciferase, which was 
originally cloned from the marine organism Renilla reniformis. These vectors intended for use as 
an internal control reporter vector and may be used in combination with any experimental 
reporter vector to co-transfect mammalian cells. The pRL-CMV Vector (Promega, Ref.E2261) 
was used in the transfection assays of this study. This vector contains the CMV enhancer and 
immediate/early promoter elements to provide high-level expression of Renilla luciferase in co-
transfected mammalian cells. 
 
 
8.1.4. Expression vectors 
 
pcDNA3 – Eukaryotic expression empty vector. 
 
pcDNA3-CREB - The pcDNA3-CREB expression plasmid was subcloned from pSVCREB in 
pcDNA3 (Invitrogen) with HidIII/ XbaI restriction sites. 
 
pcDNA3-KCREB – The pcDNA3-KCREB expression plasmid was subcloned from pSVKCREB 
in pcDNA3 with HidIII/ XbaI restriction sites. 
 
pcDNA3-FOXA2 – The pcDNA3-FOXA2 expression plasmid was subcloned from pSV-FOXA2 
in pcDNA3 with HidIII/ BamHI restriction sites. 
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8.2. Primer Design (5’ - 3’) 
 
8.2.1. Cloning 
Mouse PGC1- α promoter constructs 
 
Wild type (-2010;-51) 
Forward (DH1384)     
 
5’ -  ACGCGTTGATCCCAGGGTTGTCTCTC - 3’ (-2010;-1990) 
 
Reverse (DH1385)   
 
 5’ - CTCGAGCACACAGCACACACTCATGC - 3’ (-71;-51) 
 
 
 
Mouse Fsp27 promoter constructs 
 
Wild type (-2054;+1) 
Primer Forward (DH1303)  
 
5’ – TTAACGCGTCTGCAACTCATTCTGTAGCCC - 3’ (-2054;-2075) 
 
Primer Reverse (DH1304)  
 
5’ – TTACTCGAGGGCAATACCGCGTGGCCAG - 3’ (-27;+1) 
 
 
 
 
8.2.2. Site Directed Mutagenesis 
 
Mutagenic primers introduce specific experimental mutations. The mutagenic oligonucleotide 
primers must be designed individually according to the desired mutation. The following 
considerations should be made for designing mutagenic site and selection primers: 
 
1. Both the mutagenic primers must contain the desired mutation and anneal to the same 
sequence on opposite strands of the plasmid. 
 
2. Primers should be between 25 and 45 bases in length, and the melting temperature (Tm) of 
the primers should be greater than or equal to 78°C. The following formula is commonly used 
for estimating the Tm of primers: 
Tm = 81.5 + 0.41(%GC) − 675 /N − % mismatch 
 
where N is the primer length in base pairs. 
 
3. The desired mutation (deletion or insertion) should be in the middle of the primer with ~10–15 
bases of correct sequence on both sides. 
 
4. The primers optimally should have a minimum GC content of 40% and should terminate in 
one or more C or G bases. 
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5. Primers need not be 5´ phosphorylated but must be purified either by fast polynucleotide 
liquid chromatography (FPLC) or by polyacrylamide gel electrophoresis (PAGE). Failure to 
purify the primers results in a significant decrease in mutation efficiency. 
 
6. It is important to keep primer concentration in excess.  
 
 
 
 
CIDEC CREB site (mut1) 
 
Wild type   
5’-  GCTCTGAGCCACCA TACCTGACTTCAA CATGAAC GTTACTCCTGAC - 3’ 
 
Primer Forward (DH1392) 
5’ - GCTCTGAGCCACCA TACCTGAgTatcA CATGAAC GTTACTCCTGAC - 3’ (-384;-430) 
Primer Reverse (DH1393)   
5’ - CATTAGTAAC GTTCATG TgatAcTCAGGTA TGGTGGCTCAGAGC - 3’ (-384;-430) 
 
 
 
 
CIDEC CREB half site (mut2) 
 
Wild type 
 5’ – GGTGATGTTTGTGCGTCAGCCTCTGGAGGCTCCGGGTGAGAGAGAGGGG - 3’  
 
Primer Forward (DH1394) (-1799;-1848) 
5’ – GGTGATGTTTGTGatcgcGCCTCTGGAGGCTCCGGGTGAGAGAGAGGGG - 3’  
Primer Reverse (DH1395) (-1799;-1848) 
5’ -  CCCCTCTCTCTCACCCGGAGCCTCCAGAGGCgcgatCACAAACATCACC -  3’  
 
 
 
 
 
 
